Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Cutaneous Squamous Cell Carcinoma (CSCC) Market Growth in 2025?
In recent times, the market size for cutaneous squamous cell carcinoma (cSCC) has witnessed substantial growth. It is projected to expand from $7.45 billion in 2024 to $7.90 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.1%. The growth observed in the past years is due to factors such as increased instances of non-melanoma skin cancers, a burgeoning elderly population, higher exposure to ultraviolet radiation, enhancement in healthcare facilities, and a burgeoning application of immunotherapy in the field of oncology.
What Is the Forecast for the Cutaneous Squamous Cell Carcinoma (CSCC) Market Size Through 2029?
The market size for cutaneous squamous cell carcinoma (cSCC) is anticipated to experience robust expansion in the coming years. It is predicted to escalate to $9.90 billion by 2029, with a compound annual growth rate (CAGR) of 5.8%. The expansion during the forecast timeline can be credited to enhanced availability of target-specific therapies, increased awareness about skin cancer prevention, growth of medical tourism for cancer procedures, rising uptake of minimally invasive surgical procedures and encouraging governmental initiatives towards cancer care. The period of forecast will witness significant advancement in dermatology diagnostics, the evolution of sophisticated radiotherapy techniques, technological fusion in dermatology, breakthroughs in immunotherapy treatments, and progression in photodynamic therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp
What are the Key Market Players in Cutaneous Squamous Cell Carcinoma (CSCC) Market and How They’re Evolving?
Major companies operating in the cutaneous squamous cell carcinoma (CSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.
What Are the Primary Growth Drivers in the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
The rise in awareness about skin cancer is expected to drive the expansion of the cutaneous squamous cell carcinoma (cSCC) market in future. Skin cancer, which results from the abnormal proliferation of skin cells usually brought on by excessive UV exposure, can be either benign or life-threatening. Enhanced public health initiatives, better availability of information and a focus on early detection and prevention are resulting in heightened awareness about skin cancer. This, in turn, is leading to an increased demand for diagnostic and treatment options. Cutaneous squamous cell carcinoma (cSCC) plays a crucial role in providing superior skin cancer care as it aids in targeted treatments, boosts the diagnostic process, and contributes to better patient outcomes, thereby facilitating more effective management of the disease. For example, the American Cancer Society, a US-based non-profit organization committed to cancer eradication, reported that in January 2024, there were 104,930 confirmed skin cancer cases in 2023, signifying a 3.2% rise from the 108,270 cases noted in 2022. As such, the escalating awareness about skin cancer is likely to invigorate the cutaneous squamous cell carcinoma (cSCC) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21163&type=smp
What Are the Leading Segments in the Global Cutaneous Squamous Cell Carcinoma (CSCC) Industry?
The cutaneous squamous cell carcinoma (CSCC) market covered in this report is segmented –
1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
What Are the Key Market Trends in the Cutaneous Squamous Cell Carcinoma (CSCC) Industry?
Leading firms engaged in the cutaneous squamous cell carcinoma (cSCC) market are prioritizing advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted treatments, to enhance the prognosis of patients and offer efficacious solutions for severe skin cancer management. PD-L1, also known as programmed death-ligand 1, is an immune-suppressing protein that connects to PD-1 receptors on T-cells, thus assisting cancer cells to dodge immune detection. For instance, in December 2024, Checkpoint Therapeutics Inc., an American biotech firm, obtained FDA consent for Unloxcyt (cosibelimab-ipdl). The breakthrough feature of this treatment is its capacity to obstruct PD-L1, thereby amplifying the immune system’s combat against cancer and introducing a safer and more potent treatment alternative. Moreover, its dual modes of operation signify a hopeful strategy for handling progressive cutaneous squamous cell carcinoma (cSCC). The endorsement was driven by outcomes from the CK-301-101 trial, which indicated clinically significant objective response rates and sustainable responses in advanced cSCC patients.
Access The Full Report Here:
What Is the Regional Outlook for the Cutaneous Squamous Cell Carcinoma (CSCC) Market?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (CSCC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21163
This Report Delivers Insight On:
1. How big is the cutaneous squamous cell carcinoma (cscc) market, and how is it changing globally?
2. Who are the major companies in the cutaneous squamous cell carcinoma (cscc) market, and how are they performing?
3. What are the key opportunities and risks in the cutaneous squamous cell carcinoma (cscc) market right now?
4. Which products or customer segments are growing the most in the cutaneous squamous cell carcinoma (cscc) market?
5. What factors are helping or slowing down the growth of the cutaneous squamous cell carcinoma (cscc) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model